Strides Pharma Ltd Q3FY23 loss ₹80.02 Cr- consolidated

Strides Pharma Ltd Q3FY23 loss ₹80.02 Cr- consolidated

Strides Pharma Ltd has announced Consolidated financial results for the quarter ending December 31, 2022.

Financial Results (Q3 FY2023) – Quarter-over-Quarter Comparison:

Total income of Strides Pharma Ltd for Q3 FY2023 was Rs. 891.046 crores, a decrease from Rs. 920.556 crores in Q2 FY2023.

Net profit/loss for Q3 FY2023 was Rs. -80.026 crores, a decrease from a net profit of Rs. 22.825 crores in Q2 FY2023.

Earnings per share for Q3 FY2023 was Rs. -8.86, a decrease from Rs. 2.54 in Q2 FY2023.

FinancialsQ3 FY2023Q2 FY2023% Change
Total Income₹891.046 Cr₹920.556 Cr🠋 -3.21%
Net Profit₹-80.026 Cr₹22.825 Cr🠋 -450.61%
EPS₹-8.86₹2.54🠋 -448.82%

Financial Results (Q3 FY2023) – Year-over-Year Comparison:

Total income of Strides Pharma Ltd for Q3 FY2023 was Rs. 891.046 crores, an increase from Rs. 804.582 crores in Q3 FY2022.

Net profit/loss for Q3 FY2023 was Rs. -80.026 crores, an improvement from a net loss of Rs. -121.671 crores in Q3 FY2022.

Earnings per share for Q3 FY2023 was Rs. -8.86, an improvement from Rs. -13.55 in Q3 FY2022.

FinancialsQ3 FY2023Q3 FY2022% Change
Total Income₹891.046 Cr₹804.582 Cr🠉 10.75%
Net Profit₹-80.026 Cr₹-121.671 Cr⬇ 34.23%
EPS₹-8.86₹-13.55⬇ 34.61%

Financial Results (9 Months Ended FY2023) – Year-over-Year Comparison:

Total income of Strides Pharma Ltd for the 9 months ended December 31, 2022 was Rs. 2765.224 crores, an increase from Rs. 2250.163 crores in the same period of FY2022.

Net profit/loss for the 9 months ended December 31, 2022 was Rs. -193.093 crores, an improvement from a net loss of Rs. -489.430 crores in the same period of FY2022.

Earnings per share for the 9 months ended December 31, 2022 was Rs. -21.45, an improvement from Rs. -54.54 in the same period of FY2022.

Financials9 Months Ended FY20239 Months Ended FY2022% Change
Total Income₹2765.224 Cr₹2250.163 Cr🠉 22.89%
Net Profit₹-193.093 Cr₹-489.430 Cr⬇ 60.55%
EPS₹-21.45₹-54.54⬇ 60.67%

For More Latest News Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *